Anvisa releases diabetes medicine to treat kidney disease; see which

Written in HEALTH he 2/5/2024 · 12:33 pm

The National Health Surveillance Agency (Anvisa) approved the use of empagliflozin medicationa medicine indicated to combat diabetes type 2for other purpose: the treatment of chronic kidney disease (CKD).

The agency’s approval was based on the study EMPA-KIDNEYconducted by the Population Health Research Unit at the University of Oxford, in the United Kingdom, in partnership with pharmaceutical companies Boehringer Ingelheim It is Eli Lilly.

Scientific research concluded that the molecule reduced the risk of progression of kidney disease or death from cardiovascular problems by 28% in patients with CKDcompared to people who did not receive the medicine.

Medicine is also used for heart failure

The medicine empagliflozin is also used in cases of cardiac insufficiency. From now on, with the release also for CKD, it will provide a comprehensive approach to treating metabolic cardiorenal conditions, according to the study.

The numbers related to chronic kidney disease are frightening: currently, CKD affects approximately 6 million people in Brazil.